NEW TAIPEI CITY, Taiwan — January 6, 2026 — GlycoNex, Inc. (TWO:4168) today announced that it has deployed a high-performance AI computing platform for quantum-mechanics simulation and antibody design, strengthening its capabilities for next-generation glycan-directed antibody-drug conjugate research. The system is used to evaluate the key interaction points between an antibody and its carbohydrate antigen and to optimize specificity, with the goal of designing antibodies with higher tumor selectivity.
GlycoNex has more than a decade of experience applying 3D structural simulation to antibody design and optimization, supported by an extensive antibody-development database. The newer AI computing and quantum-mechanics simulation extend this foundation — enabling analysis of antibody–antigen interactions at higher resolution and improving the efficiency of candidate screening.
By elevating computation from conventional structural modeling to the quantum-mechanics level, atomic-scale calculation can more precisely predict the electron distribution and binding energy between an antibody and a tumor-associated carbohydrate antigen. High-specificity candidates can therefore be selected at the design stage, reducing impact on healthy tissue and supporting drug safety.